Globeflex Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Globeflex Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24	Closed	-$11.2K	–	512
2024 Q3	$11.2K	Sell	24 -896	-97%	-$430K	﹤0.01%	424
2024 Q2	$431K	Hold	920	–	–	0.05%	262
2024 Q1	$385K	Hold	920	–	–	0.04%	280
2023 Q4	$374K	Hold	920	–	–	0.04%	287
2023 Q3	$320K	Hold	920	–	–	0.04%	285
2023 Q2	$324K	Buy	920 +7	+0.8%	+$2.36K	0.04%	288
2023 Q1	$288K	Buy	913 +12	+1%	+$3.6K	0.04%	312
2022 Q4	$260K	Hold	901	–	–	0.03%	329
2022 Q3	$261K	Hold	901	–	–	0.04%	331
2022 Q2	$254K	Sell	901 -23	-2%	-$6.16K	0.06%	304
2022 Q1	$241K	Hold	924	–	–	0.05%	332
2021 Q4	$203K	Hold	924	–	–	0.04%	353
2021 Q3	$168K	Hold	924	–	–	0.04%	348
2021 Q2	$186K	Hold	924	–	–	0.03%	377
2021 Q1	$199K	Hold	924	–	–	0.04%	376
2020 Q4	$218K	Hold	924	–	–	0.05%	378
2020 Q3	$251K	Buy	924 +165	+22%	+$45.5K	0.07%	345
2020 Q2	$220K	Sell	759 -9	-1%	-$2.44K	0.06%	389
2020 Q1	$183K	Buy	768 +759	+8,433%	+$174K	0.06%	371
2019 Q4	$2K	Hold	9	–	–	﹤0.01%	504
2019 Q3	$2K	Hold	9	–	–	﹤0.01%	489
2019 Q2	$2K	Buy	+9	New	+$1.57K	﹤0.01%	487

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Globeflex Capital's VRTX Position: Q4 2024 in Review

Globeflex Capital sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 24 shares — an estimated $11.2K sold.

Globeflex Capital first reported a position in VRTX in Q2 2019 and held it in 22 quarters. The position peaked at $431K in Q2 2024. 1,562 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Globeflex Capital reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Globeflex Capital sold 24 Vertex Pharmaceuticals shares in Q4 2024, an estimated $11.2K.
Globeflex Capital first reported a position in Vertex Pharmaceuticals in Q2 2019 and held it in 22 quarters.
Globeflex Capital's Vertex Pharmaceuticals position peaked at $431K in Q2 2024.
1,562 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Globeflex Capital's 13F filing for Q4 2024, filed 10 Feb 2025.